JP7429688B2 - シールド剤およびそれらの使用 - Google Patents

シールド剤およびそれらの使用 Download PDF

Info

Publication number
JP7429688B2
JP7429688B2 JP2021515616A JP2021515616A JP7429688B2 JP 7429688 B2 JP7429688 B2 JP 7429688B2 JP 2021515616 A JP2021515616 A JP 2021515616A JP 2021515616 A JP2021515616 A JP 2021515616A JP 7429688 B2 JP7429688 B2 JP 7429688B2
Authority
JP
Japan
Prior art keywords
cancer
compound
contrast agent
effective amount
agent conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501383A (ja
JPWO2020061293A5 (https=
JP2022501383A5 (https=
Inventor
クリストファー・ポール・リーモン
イオンチョ・ラドスラヴォフ・ヴラホフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of JP2022501383A publication Critical patent/JP2022501383A/ja
Publication of JPWO2020061293A5 publication Critical patent/JPWO2020061293A5/ja
Publication of JP2022501383A5 publication Critical patent/JP2022501383A5/ja
Priority to JP2023204832A priority Critical patent/JP7748438B2/ja
Application granted granted Critical
Publication of JP7429688B2 publication Critical patent/JP7429688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021515616A 2018-09-21 2019-09-19 シールド剤およびそれらの使用 Active JP7429688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204832A JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734690P 2018-09-21 2018-09-21
US62/734,690 2018-09-21
PCT/US2019/051903 WO2020061293A1 (en) 2018-09-21 2019-09-19 Shielding agents and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204832A Division JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Publications (4)

Publication Number Publication Date
JP2022501383A JP2022501383A (ja) 2022-01-06
JPWO2020061293A5 JPWO2020061293A5 (https=) 2022-09-29
JP2022501383A5 JP2022501383A5 (https=) 2022-09-29
JP7429688B2 true JP7429688B2 (ja) 2024-02-08

Family

ID=69887812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515616A Active JP7429688B2 (ja) 2018-09-21 2019-09-19 シールド剤およびそれらの使用
JP2023204832A Active JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023204832A Active JP7748438B2 (ja) 2018-09-21 2023-12-04 シールド剤およびそれらの使用

Country Status (5)

Country Link
US (1) US20210323985A1 (https=)
EP (1) EP3853213A4 (https=)
JP (2) JP7429688B2 (https=)
CN (1) CN113166087B (https=)
WO (1) WO2020061293A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015011118B1 (pt) * 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CA3237590A1 (en) * 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226141A1 (en) 2014-08-06 2017-08-10 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
JP2020530007A (ja) 2017-04-11 2020-10-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２−ｐｍｐａのプロドラッグ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2847275T3 (es) * 2006-11-08 2021-08-02 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2012174136A1 (en) * 2011-06-15 2012-12-20 Cancer Targeted Technology Llc Chelated psma inhibitors
BR112015011118B1 (pt) * 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226141A1 (en) 2014-08-06 2017-08-10 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
JP2020530007A (ja) 2017-04-11 2020-10-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２−ｐｍｐａのプロドラッグ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pavel Majer et al.，Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II(GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA)，Journal of Medicinal Chemistry，2016年，59巻，2810-2819頁
Theranostics，2016年，Vol.6, No.6, pp.849-861

Also Published As

Publication number Publication date
JP2022501383A (ja) 2022-01-06
EP3853213A1 (en) 2021-07-28
EP3853213A4 (en) 2022-07-06
US20210323985A1 (en) 2021-10-21
JP2024028840A (ja) 2024-03-05
JP7748438B2 (ja) 2025-10-02
WO2020061293A1 (en) 2020-03-26
CN113166087B (zh) 2024-05-10
CN113166087A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
JP7429688B2 (ja) シールド剤およびそれらの使用
KR102902487B1 (ko) 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도
CN110678227B (zh) 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞
JP7840115B2 (ja) 癌を治療する方法
AU2019345320B2 (en) Methods of treating cancer
JP2018512390A (ja) Ｐｓｍａリガンド−チューブリシン化合物を用いた癌の処置方法
RU2811406C2 (ru) Способы лечения рака
RU2825637C2 (ru) Способы лечения рака
HK40047004A (en) Methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240129

R150 Certificate of patent or registration of utility model

Ref document number: 7429688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150